Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34309623.
- Also identified by DOI 10.1001/jamainternmed.2021.3779 and PMC identifier 8314170.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case series study examines the safety of second doses of messenger RNA COVID-19 vaccines after first-dose allergic reactions.
Medical subject headings
- COVID-19 Vaccines